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Background: Epithelial ovarian cancer (EOC) is the most common cause of gynecological malignancy-related mortality.
Ovarian clear cell carcinoma (CCC) has unique clinical characteristics and behaviors that differ from other histological types
of EOC, including a frequent association with endometriosis and a highly chemoresistant nature, resulting in poor prognosis.
However, factors underlying its malignant behavior are still poorly understood. Aberrant expression of microRNAs has been
shown to be involved in oncogenesis, and microRNA-21 (miR-21) is frequently overexpressed in many types of cancers. The
aim of this study was to investigate the role of miR-21 in 17q23-25 amplification associated with CCC oncogenesis.
Methods:We identified 17q23-25 copy number aberrations among 28 primary CCC tumors by using a comparative
genomic hybridization method. Next, we measured expression levels of the candidate target genes, miR-21 and PPM1D,
for 17q23-25 amplification by real-time RT-PCR analysis and compared those data with copy number status and
clinicopathological features. In addition, immunohistochemical analysis of PTEN (a potential target of miR-21)
was performed using the same primary CCC cases. We investigated the biological significance of miR-21 overexpression
in CCC using a loss-of-function antisense approach.
Results: 17q23-25 amplification with both miR-21 overexpression and PTEN protein loss was detected in 4/28 CCC cases
(14.2%). The patients with 17q23-25 amplification had significantly shorter progression-free and overall survival
than those without 17q23-25 amplification (log-rank test: p = 0.0496; p = 0.0469, respectively). A significant correlation
was observed between miR-21 overexpression and endometriosis. Both PTEN mRNA and PTEN protein expression were
increased by miR-21 knockdown in CCC cells. We also confirmed that miR-21 directly bound to the 3′-untranslated
region of PTEN mRNA using a dual-luciferase reporter assay.
Conclusions: MiR-21 is a possible driver gene other than PPM1D for 17q23-25 amplification in CCC. Aberrant expression
of miR-21 by chromosomal amplification might play an important role in CCC carcinogenesis through the regulation of the
PTEN tumor suppressor gene.
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Epithelial ovarian cancer (EOC), a heterogeneous group
of neoplastic diseases that arise from the epithelial cells
of fallopian tubes, ovarian fimbria, ovarian surface epi-
thelium, inclusion cysts, peritoneal mesothelium, or
endometriosis, is the most lethal gynecologic malignancy* Correspondence: yanazou@jikei.ac.jp
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unless otherwise stated.in western countries and in Japan [1]. EOC can be classi-
fied into four major histological types: serous, mucinous,
endometrioid adenocarcinoma, and clear cell carcinoma
(CCC). CCC has unique clinical characteristics that differ
from other histological types of EOC. CCC accounts for
5–25% of all EOC, depending on the population. The
prevalence of CCC among EOCs in North America and
Europe is 1–12%, while that in Japan is approximately
20% [2]. CCC is frequently associated with coexistent
endometriosis and thrombosis, with 20% of patientstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been identified in more than 30% of tumors and is re-
ported to be a precursor of CCC as well as endome-
trioid adenocarcinoma [3]. The incidence of venous
thromboembolic events was found to be significantly
higher in CCC than in other epithelial ovarian cancers
[4,5]. A greater proportion of CCC presents in the early
stage as a large pelvic mass, which may account for their
earlier diagnosis. However, CCC is generally refractory to
standard platinum agent-based chemotherapy with a re-
sponse rate of only 11–15%; therefore, this type of tumor
typically has a poor prognosis, particularly in late stages.
The survival rates of patients with CCC are significantly
lower than those of patients with serous EOC [6]. Identify-
ing novel therapeutic targets and establishing new treat-
ment strategies for CCC is thus important.
The common molecular genetic alterations identified
so far in CCC include mutations in ARID1A and PI3K as
well as HNF1B overexpression. However, the molecular
landscape of CCC oncogenesis remains poorly understood
[7,8]. Since chromosomal aberrations are a cardinal fea-
ture of carcinogenesis, the identification of amplified or
deleted chromosomal regions associated with CCC would
elucidate its underlying pathogenetic mechanisms. Ampli-
fication at chromosome17q23-25 has been reported to
occur with a frequency of approximately 40% in CCC [9].
The PPM1D gene (also known as WIP1) maps to the
17q23.2 amplicon and is amplified and/or overexpressed
in various types of cancers, including CCC [10]. However,
the frequency of PPM1D overexpression in CCC is re-
ported to be only about 10%. In addition, the peak region
of 17q23-25 amplification in CCC as assessed by GISTIC
analysis maps adjacent to the PPM1D locus. Taken to-
gether, these findings suggest the involvement of undis-
covered driver genes on 17q23-25 in CCC [11].
Recent evidence has shown that microRNAs (miRNAs)
can have oncogenic or tumor suppressor functions and con-
tribute to cancer biology [12,13]. Aberrant expression of
miRNAs has been shown to be associated with oncogenesis.
One of the most frequently overexpressed miRNAs in many
types of cancers is miRNA-21, located on 17q23.2 within the
intron of the TMEM49 gene [14]. Protein expression of the
PTEN gene, a target gene of miR-21 [15], is absent in one-
third of all CCC cases [16,17]. We thus hypothesized that
miR-21 is a potential candidate for 17q23-25 amplification
and might play an important role in CCC oncogenesis
through the regulation of PTEN expression.
Methods
Clinical specimens and ovarian cancer cell cultures
Tissue specimens were obtained from 28 patients with
ovarian CCC who were treated at Jikei University Hospital
from 2000 to 2010. The Jikei University School of Medicine
Ethics Review Committee approved the study protocol(ethics approval number: 14-132) and informed consent was
obtained from all patients. Most patients (27 of 28) under-
went surgical resection followed by adjuvant chemotherapy
with platinum-based regimens (platinum/paclitaxel, n = 12;
platinum/irinotecan hydrochloride, n = 13; docetaxel/
carboplatin, n = 2) as initial treatment. None of the patients
had received chemotherapy or radiation therapy before the
initial surgery. All samples were examined as hematoxylin–
eosin-stained sections by a pathologist to confirm pure
CCC histologically. Tumors were classified according to
the World Health Organization classification system, and
clinical stages were determined using the International Fed-
eration of Gynecology and Obstetrics (FIGO) staging sys-
tem. Progression-free survival (PFS) was defined as the
time from the date of primary surgery to the date of disease
progression. Overall survival (OS) was calculated for the
time from the date of initial surgery to the last follow-up
visit or death. The mean age was 53 years (range, 37–81).
FIGO staging was as follows: Stage I, n = 18; stage II,
n = 2; stage III, n = 8. The median follow-up period
was 45.7 months (range, 5.1–99.3). Coexistent endo-
metriosis was found in 20 (71.4%) of 28 patients. The
ovarian CCC cell lines JHOC-5 and JHOC-9 were obtained
from Riken Bioresource center (Tsukuba, Japan). HAC-2
was kindly provided by Dr. Nishida (Tsukuba University,
Ibaraki, Japan). RMG-I and RMG-II were provided by
Dr. D. Aoki (Keio University, Tokyo, Japan). HAC-2,
JHOC-5, and JHOC-9 cells were cultured in RPMI-1640
medium (Sigma-Aldrich, Tokyo, Japan). RMG-I and RMG-II
were cultured in Ham F-12 medium (Sigma-Aldrich). Both
media contained 10% heat inactivated fetal bovine serum,
Penicillin-Streptomycin-Amphotericin B Suspension (×100)
(Wako, Osaka, Japan). Cells were incubated at 37°C in a
humidified atmosphere containing 5% CO2.
DNA and RNA isolation
All surgical samples were composed of at least 80% neo-
plastic cells and were immediately frozen after collec-
tion. For RNA isolation, the fresh clinical specimens
were stored at 4°C for 24 hours in RNAlater (Ambion,
Austin, Texas, USA) and were then frozen at −80°C in
liquid nitrogen until further use. Using a commercially
available DNA isolation kit (GentraPureGene kit; Qiagen,
Tokyo, Japan), genomic DNA was extracted from stored
frozen tumor samples following the manufacturer's instruc-
tions. Total RNA was isolated from tumor samples and cell
lines with Trizol reagent (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. Total RNA
from the tumor samples was stored in RNAlater.
Candidate gene selection
Array comparative genomic hybridization (aCGH)
For this validation study, aCGH was performed using
the Agilent Human Genome CGH 244AMicroarray Kit
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digestion, labeling, and hybridization were performed as
recommended by the manufacturer. The test DNA (2 μg)
and reference DNA (2 μg) were digested with Rsa I and
Alu I (Promega). The digested tumor DNA and reference
DNA were labeled with either cyanine (Cy) 5-deoxyuridine
triphosphate (dUTP) or Cy3-dUTP using the Agilent
Genomic DNA Labeling Kit PLUS (Agilent Technologies).
Labeled DNAs were purified using Microcon YM-30 filters
(Millipore, Billerica, MA, USA). The hybridization mixture,
containing Cy3-labeled test DNA and Cy5-labeled refer-
ence DNA, 2× Hybridization buffer (Agilent), 10× blocking
agent (Agilent), and Human Cot-1 DNA (Invitrogen), was
prepared in an Agilent SureHyb chamber. All microarray
slides were scanned on the Agilent Microarray Scanner
G2505B. Date was obtained using Feature Extraction soft-
ware, version 10.7.3.1 (Agilent Technologies). Penetrance
of aberrant chromosomal areas across the genome was
demonstrated using Aberration Detection Method 2 (Agi-
lent Genomic Workbench Lite Edition 6.5.0.18, Agilent
Technologies), a quality-weighted interval score algorithm
that identifies aberrant intervals in samples that have con-
sistent gain or loss log ratios based on their statistical score.
The log2 ratios for whole chromosomal number changes
that were completely gained, lost, or had no change were
evaluated. The threshold for determining amplification or
deletion was defined as log2 ratio >0.5 or < −0.5.
Copy number assay for region 17q23–25 in the miR21 gene
in CCC cells
The copy number for the 17q23–25 region was deter-
mined using commercially available and custom TaqMan
Copy Number Assays (Applied Biosystems, Foster City,
CA, USA). The TERT locus was used as an internal ref-
erence copy number. Genomic DNA was extracted from
CCC cell lines (HAC-2, JHOC-5, JHOC-9, RMG-I, and
RMG-II) using commercially available gDNA extraction
and purification kits. Real-time genomic PCR was performed
in a total volume of 20 μL per well containing TaqMan
genotyping master mix (10 μL), genomic DNA (20 ng), and
primers (20 ng each). Data were analyzed using SDS
2.2 sand CopyCaller software (Applied Biosystems).
Copy numbers were assigned as follows: actual copy
number <0.5, assigned copy number 0 (gene deletion);
actual copy number ≥0.5 but <1.5, assigned copy number 1;
actual copy number ≥1.5 but <2.5 , assigned copy number 2;
actual copy number ≥2.5 but <3.5, and assigned copy
number 3.
Quantitative reverse transcription-polymerase chain
reaction
Reverse transcription (RT) of miR-21 was carried out using
the Taqman microRNA reverse transcription kit (Applied
Biosystems, Foster City, CA, USA). cDNAs were synthesizedfrom 2 μg of total RNA using the Superscript cDNA
Synthesis Kit (Invitrogen) for PPM1D and PTEN mRNA
detection. Real-time PCR Reactions with TaqMan Fast
Advanced Master Mix (Applied Biosystems) were per-
formed in 96-well plates using the Applied Biosystems
StepOnePlus Real-time PCR System (Applied Biosystems).
Each reaction was analyzed in triplicate. MiR-21 expres-
sion was normalized to that of U6 small nuclear RNA,
and PPM1D and PTEN expression was normalized to that
of GAPDH. The expression of miR-21, PPM1D, and PTEN
were defined based on the threshold cycle (Ct); relative
expression levels are presented as 2–ΔΔCt.
Immunohistochemical analysis
Immunohistochemical analysis of PTEN expression (1:100
dilution, Cell Signaling Technologies) was performed
on 3-μm paraffin sections of formalin-fixed, paraffin-
embedded tissues using the Ventana Discovery XT auto-
mated stainer (Ventana Medical Systems, Tucson, AZ,
USA). After deparaffinization, antigen retrieval was carried
out in CC1 buffer (Cell Conditioning 1; citrate buffer
pH 6.0, Ventana Medical Systems). PTEN expression
was scored independently by two investigators (Y. H.
and N. Y.) based on stain intensity and extent. Immu-
nohistochemical scoring was conducted in a manner
entirely blinded to all clinical and biological variables.
The intensity of positive staining was scored from 0 to
2 as follows: 0 (none), 1 (weak; intensity < positive control),
2 (strong; intensity ≥ positive control). Positive staining was
assigned using a semi-quantitative, five-category grading sys-
tem: 0, <5% positive cells; 1, 6–25% positive cells; 2, 26–50%
positive cells; 3, 51–75% positive cells; 4, 76–100% positive
cells. Addition of the two values gives the total score, and a
score <4 was considered PTEN-negative.
Additional cohort
Additional cohort study was also approved by The Jikei
University School of Medicine Ethics Review Committee
(ethics approval number: 14-132). An additional cohort
was analyzed using aCGH, realtime-PCR, and immuno-
histochemistry. This additional cohort was included to
ensure association between miR21 overexpression and
PTEN protein loss using 43 patients, with further con-
firmation in an additional 15 patients.
Western blot analysis
Western blot analysis was performed to detect PTEN
protein expression (dilution of 1:2000, Cell Signaling
Technologies, Danvers, MA, USA). CCC cell lines were
washed in PBS and lysed in RIPA buffer containing
200 mM Tris-HCl (pH 7.2), 150 mM NaCl, 0.1% SDS,
1% Nonidet P-40, 1% sodium deoxycholate, 2 mM
EDTA, 50 mM NaF, 1% proteinase inhibitors, and 1%
PMSF for 10 min on ice. Cell lysates were then sonicated
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centrifugation at 14 000 rpm at 4°C for 30 min. Super-
natants were collected and assayed for protein concen-
tration using the BCA Protein Assay Kit (Invitrogen).
Supernatants containing an equal amount of protein
extract were supplemented with concentrated 4× LDS
sample buffer (Invitrogen) and heated at 95°C for 5 min.
Approximately 40 μg of lysate was loaded onto a 12.5%
SDS-polyacrylamide gel. The supernatants were sepa-
rated by SDS–PAGE, and proteins were transferred to
Immobilon-P transfer membrane (Millipore, Milford,
MA, USA). The transfer membrane was incubated with
primary antibody in TBS with 0.1% Tween-20 and 5%
bovine serum albumin overnight at 4°C. Anti-rabbit
IgG-conjugated horseradish peroxidase (GE Healthcare)
was used as the secondary antibody. The transfer mem-
brane was incubated with secondary antibody in TBS with
0.1% Tween-20 and 5% skim milk for 90 min at room
temperature. The proteins were visualized using the ECL-
Plus Western blotting detection system and detected using
the Image Quant LAS 4000 mini (GE Healthcare). The
concentration of each target protein was normalized
against beta-actin.
Transfection
Twenty four hours before transfection, cells were seeded
in plates and grown to 50% confluence. For inhibition of
miR-21, RMG-II cells were transfected with mirVana
miRNA Inhibitors or a control (Ambion). Transfections
were performed using Lipofectamine RNAiMAX (Invi-
trogen) according to the manufacturer’s protocol.
Dual luciferase reporter assay
pGL3 wild-type PTEN 3′-UTR and pGL3 mutant-type
PTEN 3′-UTR luciferase plasmids were obtained from
Addgene (Cambridge, MA). RMG-II cells were seeded in
6-well plates (5×105 cells/well). After 24 h, the cells were
transfected with pGL3 control vector (Promega), pGL3
wild-type PTEN 3′-UTR vectors, or pGL3 mutant-type
PTEN 3′-UTR vectors using Lipofectamine 2000 reagent.
Luciferase activities were measured using the Dual-
Luciferase Reporter Assay system (Promega) 24 h after
transfection. Firefly luciferase activity was normalized
to renilla activity for each sample. All the experiments
were performed in triplicate.
MTS assay
MTS assay was performed using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay kit (Promega,
Madison, WI, USA) following the manufacturer's protocol.
Briefly, miR-21 inhibitor and negative control oligonucleo-
tides were transfected at a final concentration of 200nM.
After 24 hours transfection, RMG-II cells were seeded into
96-well plates at a density of 1 × 104 cells per well. MTS(20 μL) was added to each well 3 hours before the desired
time points, and cells were incubated at 37°C. The ab-
sorbance was measured at 490 nm using a Microplate
Reader (VersaMAx, Molecular Devices). All experiments
were repeated three times. Values are presented as the
mean ± standard deviation (SD).
Invasion assay
Cells were seeded into the top chamber of a 96-well
matrigel-coated plate with 8-μm-pore polyethylene ter-
ephthalate membrane inserts (Corning). MiR-21 inhibitor
and negative control oligonucleotides were transfected at
a final concentration of 200nM.The bottom chamber was
filled with 0.75 mL Ham F-12 medium with 10% FBS as a
chemoattractant. The inserts were filled with 0.5 mL Ham
F-12 medium with 1% FBS. After incubation for 48 h, the
filter membrane was fixed with 100% methanol and
stained with hematoxylin and eosin. The degree of inva-
siveness was quantified by counting the number of cells in
4 random fields of view per filter using 400× magnifica-
tion. Data obtained from three separate inserts are shown
as mean values.
Statistical analysis
All statistical analyses were performed using StatMate III
software (ATMS, Tokyo, Japan). Comparisons between pa-
rameters were made using Fisher’s exact test. For survival
analysis, PFS and OS distributions were determined using
the Kaplan–Meier method, and the resulting curves were
compared using the log-rank test. P <0.05 was considered
statistically significant.
Results
Chromosome 17q23-25 amplification, miR-21 expression,
and PTEN protein expression in CCC
CGH array profiles of chromosome 17 in 28 primary
CCCs revealed that 9 out of 28 patients (32%) showed
17q23-25 amplification that included miR-21 (Figure 1).
MiR-21 and PPM1D mRNA expression were then mea-
sured by real-time RT-PCR analysis (Additional file 1:
Figure S1). We defined standardized value as each me-
dian value of miR-21 and PPM1D expression without
17q23-25 amplification. Overexpression of miR-21 and
PPM1D were found in 60% and 57% of these tumors, re-
spectively. Seven of 9 tumors (77.7%) with 17q23-25
amplification showed miR-21 overexpression, and 10 of
19 tumors (52.6%) without 17q23-25 amplification also
showed miR-21 overexpression. In addition, 6 of 9 tumors
(66.6%) with 17q23-25 amplification showed PPM1D over-
expression, and 10 of 19 tumors (52%) without 17q23-25
amplification showed PPM1D overexpression (Additional
file 1: Figure S1). We next evaluated the relationship
between 17q23-25 amplification and either miR-21 or
PPM1D overexpression. No significant correlation between
Figure 1 Frequency of copy number changes in chromosome 17 by array CGH in 28 CCC. (A) chromosome 17 is represented by ideograms
showing G-banding patterns. Bold vertical lines on the ideogram indicate the region of chromosomal amplification. The number at the top of each
line represents the primary tumor in which the indicated change was recorded. Nine samples showed 17q23-25 amplification that included miR-21.
(B) The gains and losses are shown as green and red color bars, respectively. These samples showed 17q23-25 amplification that included miR-21.
Figure 2 Analysis of clinical CCC specimens. Of the 9 tumors
with 17q23-25 amplification, 7 (77.7%) showed miR-21 overexpression.
Of the 19 tumors (58.8%) without 17q23-25 amplification, 10 showed
miR-21 overexpression. Of all the 28 17q23-25 amplification cases,
both miR-21 overexpression and PTEN protein loss were detected
in 4 (14.2%).
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either gene. Next, immunohistochemical analysis of PTEN
(a potential target of miR-21) was performed on samples
from the same primary CCC patients. Loss of PTEN
protein was observed in 13 of 28 patients (46.4%) (Additional
file 2: Figure S2) and in 6 of 17 tumors (35.3%) with miR-21
overexpression. No significant correlation was observed
between miR-21 overexpression and loss of PTEN ex-
pression. To further confirm these results, we added
15 CCC samples from an additional cohort, performing
real-time RT-PCR of miR21 and IHC of PTEN. Again,
no significant correlation was observed between miR-21
overexpression and loss of PTEN expression (date not
shown). In total, as shown in Figure 2, the occurrence of
17q23-25 amplification with both miR-21 overexpression
and PTEN protein loss was detected in 4 out of 28 CCC
patients (14.2%) (Figure 2).
Associations between clinicopathological parameters and
either 17q23-25 amplification, miR-21 overexpression, or
PTEN protein loss
The relationship between clinicopathological parameters and
genetic alterations including 17q23-25 amplification, miR-21
overexpression, and decreased PTEN protein expression are
summarized in Table 1. Interestingly, a significant cor-
relation was observed between miR-21 overexpressionand endometriosis. Meanwhile, no correlations were
observed between the other clinical parameters and
any of the genetic alterations. According to survival
analysis, patients with 17q23-25 amplification had sig-
nificantly shorter progression-free and overall survival
times than did those without 17q23-25 amplification
(log-rank test; PFS, p = 0.0496; OS, p = 0.0469) (Table 2).
On the other hand, the PFS and OS did not correlate
significantly with miR-21 overexpression or PTEN pro-
tein loss.
Table 1 Associations between clinicopathological parameters and either 17q23-25 amplification, miR-21 overexpression,
or PTEN protein loss
Variable Cases
(Total 28)
17q23-25 amplification miR-21 overexpression Loss of PTEN protein expression
n = 9 P value n = 17 P value n = 13 P value
Age 6 4 >0.9999 5 0.0690
≧60 22 2 >0.9999 13 8
< 60 7
Stage 0.6464 >0.9999 8 0.1977
I-II 21 6 11 5
III-IV 7 3 4
Lymph node status 7 >0.9999 4 0.6702
Metastasis 21 3 0.6219 4 9
No metastasis 6 11
Endometriosis 8 0.2143 15 10 0.6859
Positive 20 1 2 0.0298 3
Negative 8
Thrombosis 3 1 >0.9999 2 >0.9999 2 0.5833
Positive 25 8 13 11
Negative
No correlations were observed between the other clinical parameters (age, stage, lymph node metastasis, thrombosis, and either 17q23-25 amplification,
miR-21 overexpression, or PTEN protein loss). A significant correlation was observed between miR-21 overexpression and endometriosis. P-values were
from two-sided tests and statistically significant when <0.05.
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Based on the profiles of 17q23-25 copy number changes,
miR-21 expression, PTEN mRNA expression, and PTEN
protein expression in 5 CCC cell lines, we selected RMG-
II cells for further functional analysis. We considered this
cell line to be ideal because the cells showed relatively
17q23-25 amplification, high miR-21 expression with
decreased PTEN protein expression (Additional file 3:
Figure S3 and Additional file 4: Figure S4).
To investigate the regulation of PTEN expression by
miR-21 in CCC, we used a loss-of-function antisense ap-
proach in RMG-II cells. Knockdown efficiency was con-
firmed by real-time RT-PCR analysis of miR-21 (Figure 3A).Table 2 Proportional hazard regression analysis of single pre
Parameters PFS
95%CI
Age (≦60 vs. >60 years) 0.289–1.656
Stage (I, II vs. III, IV) 0.289–1.234
Endometriosis 0.153–2.834
Residual tumor ≦2 VS. >2 cm) 0.3440–2.484
17q23-25 amplification 0.1768–1.684
miR-21 overexpression 0.441–1.168
PTEN protein loss 0.4422–1.980
PFS, progression-free survival; OS, Overall survival; CI, Confidence interval.
For survival analysis, PFS and OS distribution was determined using the Kaplan–Me
PFS and OS than that did those without 17q23-25 amplification in CCC tumors Mea
PTEN protein loss, or clinicopathological date.In RMG-II cells, we found that miR-21 knockdown caused a
significant increase in PTEN protein expression as indicated
by Western blot analysis, along with increased PTENmRNA
expression (Figure 3A). However, suppression of miR-21 ex-
pression did not inhibit cell proliferation or invasion (date
not shown). We next investigated the direct binding of miR-
21 to the 3’UTR of PTEN mRNA by luciferase assay using a
pGL3 plasmid harboring either the wild- or mutant-type
PTEN 3’-UTR. The activity of the luciferase reporter was
significantly decreased when fused to the wild-type PTEN
3′-UTR. Deletion mutations in the miR-21–interacting seed
region rescued the luciferase activity. Taken together, these










ier method. The patients with 17q23-25 amplification had significantly shorter
nwhile, PFS and OS did not show significant correlations in miR-21 overexpression,
Figure 3 miR-21 modulates PTEN tumor suppressor gene expression. To evaluate the biological significance of miR-21 overexpression in
CCC, we used a loss-of-function antisense approach. An antisense miR-21 oligonucleotide (ODN) was used to knock down miR-21 expression in
RMG-II cells. (A) Efficiency of RMG-II cell transfection was confirmed by real- time RT PCR. PTEN mRNA expression was increased by knockdown of
miR-21 in RMG-II cells. Western blot analysis showing that PTEN expression was increased in RMG-II cells upon inhibition ofmiR-21. (B) MiR-21 directly
targets the 3'-UTR of PTEN mRNA. The activity of luciferase in the pGL3 wild-type PTEN 3′-UTR was downregulated compared to pGL3 mutant-type
PTEN 3’-UTR and the pGL3 control in RMG-II cells. P <0.05 according to the t-test.
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CCC (Figure 3B). Several potential miR21 targets that
could have implications in CCC were identified using
web-based computational approaches to predict gene
targets (miRBase Targets BETAVersion 1.0, PicTar predic-
tions, and TargetScan). Three putative target genes,
PDCD4, SMARCA4, and SPRY2, were predicted by 3
different programs. This result indicates that tumor
suppressor genes are potentially regulated by miR21.
Therefore, we performed real-time RT-PCR for PDCD4,
SMARCA4, SPRY2 in the miR21 knockdown experiments
in RMG-II cells. We found that miR-21 knockdown in-
creased the expression of these mRNAs (Additional
file 5: Figure S5). To investigate the regulation of PTEN
expression by miR-21 in JHOC9 cells, we overexpressed
miR21 using miR21 mimics in JHOC9 cell. Quantitative
real-time PCR analysis confirmed the level of miR21
was significantly overexpressed. As expected, the level
of PTEN mRNA was downregulated in JHOC9 cells.
Expression of PDCD4, SMARCA4, and SPRY2 mRNA
was also decreased by the overexpression of miR-21 in
response to miR-21 mimics in JHOC9 cells (Additional
file 6: Figure S6).Discussion
DNA copy number aberrations are a frequent event in
many malignant tumors, leading to altered expression
and function of genes residing within the affected gen-
ome region. Such genomic abnormalities can harbor ei-
ther oncogenes or tumor suppressor genes depending
on the original gene function and whether the copy
number is amplified or deleted. Previous studies have
identified a high frequency of copy number amplifications
in CCC, including 17q23-25 (18-40%), 20q13 (22-25%),
and 8q21q- 24q. Additionally, deletions at chromosome
9q and 19p have been also reported in CCC [9,18-20].
Of the chromosomal alterations associated with CCC,
17q23-25 is one of the most frequently amplified regions
and is reported to be associated with patient outcome [9].
So far, PPM1D and APPBP2 have been identified as poten-
tial targets of 17q23-25 amplification in CCC. However, a
recent report suggests there might be new driver genes
other than PPM1D and APPBP2 in this region [11]. More
than half of miRNAs have been aligned to genomic fragile
sites or frequently deleted or amplified regions in several
malignancies [21,22]. MiRNAs are a class of small, non-
coding RNA molecules that regulate gene expression
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mRNA. Among them, miR-21, located on 17q23.2, is
unique in that it is overexpressed in many cancers as
an oncogene. Previous studies have revealed several
significant miR-21 targets that might be related to car-
cinogenesis. Based on this evidence, miR-21 is a potential
candidate for 17q23-25 amplification in CCC oncogenesis.
We analyzed DNA copy number alterations at chromo-
some 17 in a panel of 28 primary CCCs using CGH array.
In our data set, 17q23-25 amplification was observed at a
frequency similar to that of previous reports. In addition,
we confirmed that 17q23-25 amplification correlated
negatively with patient prognosis, suggesting that the
chromosomal alteration might result in the overexpres-
sion of genes that contribute to the genomic instability of
CCC. Although we did not find a statistical correlation
between miR-21 overexpression and amplification of
this region, overexpression of miR-21 was observed in
60% of the CCC cases examined.
Targets of miR-21 in cancer include PTEN, PDCD4,
LRRFIP1, RECK, TIMP-3, TPM1, BTG2, and Sprty2 [23].
PTEN can restrict growth and survival signals by limit-
ing the activity of the phosphoinositide 3-kinase (PI3K)
pathway. A decrease in PTEN might cause activation of
the PI3K pathway, including Akt and mTOR, which leads
to tumor development [24]. The prominent role of PTEN
inactivation in CCC is thought to involve multiple mecha-
nisms. In our study, loss of PTEN protein was observed in
46% of CCC patients. On the other hand, low of PTEN
copy number was not indicted by CGH array (data not
shown). Furthermore, no significant correlation was ob-
served between miR-21 overexpression and loss of PTENFigure 4 Chromosome 17q23-25 amplification, miR-21 expression, an
evaluate chromosomal alterations in 28 primary CCC tumors. Nine out of 2
region that contains miR-21. Seven of 9 tumors (77.7%) with 17q23-25 amp
both miR-21 overexpression and PTEN protein loss was detected in 4/28 caexpression in our date set. Therefore, we suggest the in-
volvement of another epigenetic mechanism, such as
PTEN mutations, promoter methylation of PTEN, loss of
heterozygosity at the PTEN locus other miR are infre-
quent in CCC. Although there was no statistical correl-
ation between PTEN loss and miR-21 overexpression, the
occurrence of 17q23-25 amplification along with both
miR-21 overexpression and PTEN protein loss was de-
tected in 14% of CCC cases. Thus, this oncogenetic mech-
anism might play a prominent role in CCC. Additionally,
we showed that miR-21 inhibition significantly increased
PTEN expression in vitro. Moreover, the results obtained
from the dual luciferase reporter assay supports the idea
that miR-21 directly targets the PTEN gene, regulating the
protein expression. It is therefore possible that miRNAs
such as miR-21 modulate PTEN expression by transcrip-
tional regulation or target degradation in CCC.
Finally, we found a significant correlation between miR-21
overexpression and endometriosis in CCC. Endometriosis-
related CCC is thought to be a chronic inflammatory
disease, characterized by increased production of pro-
inflammatory cytokines such as IL-1, IL-6, IL-8, IL-10,
and TNF-α [25]. We recently reported that CCC showed
a dominant Th-2 cytokine expression pattern driven
largely by IL-6 expression [26]. In addition, IL-6 induces
miR-21 expression through a STAT3-dependent pathway
[27]. We also confirmed that IL-6 induces miR-21 overex-
pression in RMG-II (data not shown). In our study,
miR-21 overexpression was observed in 60% of the CCC
cases, regardless of 17q23-25 amplification status, suggest-
ing another mechanism might regulate miR-21 expres-
sion. miR-21 might contribute to inflammation-inducedd PTEN protein expression in CCC. CGH array was performed to
8 patients (32%) showed chromosomal amplification in the 17q23-25
lification showed miR-21 overexpression. 17q23-25 amplification with
ses (14.2%).
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http://www.biomedcentral.com/1471-2407/14/799carcinogenesis in CCC with endometriosis. We need to fur-
ther analyze miR21 expression using in situ hybridization
in the endometriotic lesions of CCC specimens. The correl-
ation between miR21 and endometriosis observed in our
study indicates a role for miR21 in precursor lesions of
ovarian CCC.Conclusions
This study is the first to indicate miR-21 as the gene of
interest in 17q23-25 amplification associated with CCC
(Figure 4). Aberrant expression of miR-21 by chromo-
somal amplification might play an important role in
CCC carcinogenesis through regulating the PTEN tumor
suppressor gene. Moreover, the modulation by miR-21
overexpression of genes other than PTEN should not be
overlooked in determining the oncogenic mechanism of
CCC.Additional files
Additional file 1: Figure S1. MiR-21 and PPM1D mRNA expression located
on 17q23- 25. Black dots indicate a cluster with 17q23-25 amplification, and
white dots indicate a cluster without 17q23-25 amplification. We measured
the median expression of miR- 21 and PPM1D mRNA and set a transverse line
as standard value. Seven of 9 tumors with 17q23-25 amplification showed
miR-21 overexpression. Six of 9 tumors with 17q23-25 amplification showed
PPM1D overexpression.
Additional file 2: Figure S2. Immunohistochemical analysis of PTEN
that might be a potential target of miR-21 was performed using the
same primary CCC cases. The intensity of positive staining was scored
from 0 to 2, while the extent of positive staining was scored from 0 to 4.
Addition of the two values gives the total score; scores >4 were
considered PTEN-positive. (A) Typical image of a PTEN-negative case.
(B) Typical image of a PTEN-positive case. Loss of PTEN protein was
observed in 13 of 28 patients (46.4%).
Additional file 3: Figure S3. Frequency of copy number changes in
Chr 17q23-25 region by copy number assay in 5 CCC cell lines. We found
the copy number was increased in RMG-I and RMG-II cells.
Additional file 4: Figure S4. MiR-21, PTEN mRNA, and PTEN protein
expression in CCC cell lines. (A) (B) Relative expression of miR-21 and
PTEN mRNA were detected with real-time RT-PCR, and the relative
amount of miR-21 was determined using 2-ΔΔCT. (C) PTEN protein was
measured by western blotting. The RMG-II cell line was selected for further
analysis, because it had the most prominently overexpressed miR-21 and
decreased PTEN protein of the CCC cell lines.
Additional file 5: Figure S5. Three putative target genes, PDCD4,
SMARCA4, and SRY2, are potentially regulated by miR21. (A) (B) (C) Real-time
RT-PCR for PDCD4, SMARCA4, SPRY2 in the miR21 knockdown experiments
in RMG-II cells. miR-21 knockdown caused an increase in mRNA expression of
these genes by real-time RT PCR in RMG-II cells.
Additional file 6: Figure S6. Mir21 modulates PTEN expression in
JHOC9 cell. To investigate the regulation of PTEN expression by miR-21 in
JHOC9 cells, we overexpressed miR21 by miR21 mimics in JHOC9 cells.
Quantitative real-time PCR analysis confirmed miR21 was significantly
overexpressed. As expected, the level of PTEN mRNA was downregulated
in JHOC9 cells. PDCD4, SMARCA4, and SPRY2 mRNAs were also reduced
by the overexpression of miR-21 in response to miR-21 mimics in JHOC9
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